Jeevan Scientific Technology Ltd

Jeevan Scientific Technology Ltd - Closure of Trading Window

AGM Details

• Date and time: 25 September 2026, 10:00–10:40 AM, held via VC/OAVM.
• Record date: 18 September 2025.
• Voting window: remote e-voting 22–24 September 2026.
• Attendance via VC: 4 promoters and 78 public.
• Scrutinizer: Aakanksha Dubey & Co.

Resolutions and outcomes

• Ordinary: Adopt standalone and consolidated financial statements; passed.
• Ordinary: Appoint Kuchipudi as director on rotation; passed 99.98% in favour.
• Ordinary: Appoint Snigdha Mothukuri as director on rotation; passed 99.98%.
• Special: Re-appoint Snigdha Mothukuri as Whole Time Director; passed.
• Special: Continue Nageswar Rao Yarllagadda as Whole Time Director beyond age 70; passed.
• Special: Re-appoint Nageswar Rao Yarllagadda as Whole Time Director; passed.
• Special: Re-appoint Suryaprakasa Rao Bommisetti as Independent Director; passed.
• Special: Appoint Kolli Srinivas Rao as Independent Director; passed.

Director changes

• Director Kuchipudi re-appointed after rotation.
• Director Snigdha Mothukuri re-appointed; later continued as Whole-Time Director.
• Continuation of Nageswar Rao Yarllagadda beyond age 70 approved.
• Nageswar Rao Yarllagadda re-appointed as Whole-Time Director.
• Suryaprakasa Rao Bommisetti appointed Independent Director.
• Kolli Srinivas Rao appointed Independent Director.

AGM Details

• Date/time: 25 Sep 2026, 10:00 IST, via VC/OAVM.
• Quorum: 82 members attended via VC.
• Record date for e-voting: 18 Sep 2025.
• Duration: 10:00–10:40 IST via VC.

Key Resolutions & Outcomes

• Resolution 1 (Ordinary): Adopt standalone and consolidated financial statements; passed 100% in favour.
• Resolution 2: Appoint Kuchipudi as director by rotation; passed 99.98% in favour.
• Resolution 3: Appoint Snigdha Mothukuri as director; passed 99.98% in favour.
• Resolution 4: Re-appoint Snigdha Mothukuri as Whole-Time Director; passed 99.98% in favour.
• Resolution 5: Continue Nageswar Yarllagadda as WTD beyond 70; passed 100% in favour.
• Resolution 6: Re-appoint Nageswar Yarllagadda as WTD; passed 100% in favour.
• Resolution 7: Re-appoint Bommisetti as Independent Director; passed 99.98% in favour.
• Resolution 8: Appoint Kolli Srinivas Rao as Independent Director; passed 99.98% in favour.

Director Changes

• Kuchipudi appointed as director by rotation.
• Snigdha Mothukuri re-appointed as director.
• Snigdha Mothukuri re-appointed as Whole-Time Director.
• Nageswar Rao Yarllagadda continuation as WTD beyond age 70.
• Nageswar Rao Yarllagadda re-appointed as WTD.
• Suryaprakasa Rao Bommisetti re-appointed as Independent Director.
• Kolli Srinivas Rao appointed as Independent Director.

Auditors & Governance

• No changes in statutory or internal audit appointments.

Related Party Transactions

• No material related party transactions approved.

Other Material Approvals

• No ESOPs, charter amendments, borrowings, or mergers reported.

FY25-26 snapshot

• Standalone revenue from operations rose to Rs 5,511.91 lakh.
• Standalone net profit after tax was Rs 165.01 lakh.
• Consolidated revenue rose to Rs 6,250.98 lakh; consolidated PAT Rs 103.33 lakh.
• Dividends were not proposed for FY25-26.
• Equity raised Rs 1,634.00 lakh; warrants Rs 350.00 lakh; unutilised Rs 900.00.
• Paid-up capital stood at Rs 1,991.89 lakh; authorized capital increased.

Capital, liquidity and funding

• Undrawn borrowing facilities stood at Rs 334.41 lakh as of 31 Mar 2026.
• Consolidated net debt to capital: Rs 1,177.87; gearing 0.14x.
• Cash & cash equivalents ended at Rs 946.79 lakh.
• Non-current borrowings Rs 1,009.92; current borrowings Rs 705.98; lease liabilities Rs 412.52.

Expansion and operations

• Added six LC-MS/MS instruments; expanded clinical and BA/BE capacity.
• 900+ BA/BE studies conducted; expanded client base.
• Regulatory footprint expanded to ANVISA, GCC, NPRA.
• Nayas Laboratories expanded into advanced drug-delivery platforms.

Geography and performance

• Domestic revenue Rs 2,806.74 lakh; exports Rs 2,586.39 lakh.
• Standalone total revenue Rs 5,393.13 lakh; consolidated Rs 6,153.71 lakh.
• Standalone EPS Rs 0.83; Consolidated EPS Rs 0.68.

Governance, subsidiaries and related party

• Kolli Srinivas Rao appointed Independent Director from 13 Aug 2026.
• Nayas Laboratories ownership reduced to 59.26%; non-controlling 40.74%.
• Naya Pharma Private Limited became Associate (31.03%); revenue nil; loss.
• KMP compensation and related parties: Rs 298.07 lakh (standalone) and Rs 397.07 lakh (consolidated).
• Loans to subsidiary Rs 599.26 lakh; to associate Rs 57.02 lakh; guarantee Rs 740 lakh.

Audits and compliance

• Statutory audit by Pavuluri & Co; internal audit by K P & Associates.
• Secretarial audit by Aakanksha Dubey & Co; SRC non-compliance noted and fixed.
• Management Discussion and Analysis; risk management policy disclosed.

Fund-raising and deviation status

• Mode of fund raising: Preferential Allotment (Equity).
• Date of raising funds: 02.01.2026; Amount raised: 3074 Lakhs.
• Report filed for quarter ended: 30 June 2026.
• Deviation/variation in use of funds raised: No.
• Monitoring agency: Not applicable.
• Original objects: No deviation; allocations unchanged.
• Utilisation status: Not disclosed due to no deviation.

Management changes – appointments & retire-by-rotation

• Re-appoint Snigdha Mothukuri as Whole Time Director for 3 years from 02.11.2026; related to Kuchipudi and Kishore.
• Continue Mr. Nageswar Rao Yarllagadda as Whole Time Director beyond age 70; subject to member approval.
• Re-appoint Mr. Nageswar Rao Yarllagadda as Whole Time Director for 3 years from 23.06.2027; shareholders' approval.
• Re-appoint Mr. Suryaprakasa Rao Bommisetti as Independent Director for 5 years from 25.03.2027; shareholders' approval.
• Appoint Kolli Srinivas Rao as additional Independent Director for 5 years from 13.08.2026; shareholders' approval.
• Re-appoint Snigdha Mothukuri as Director, retire by rotation.
• Re-appoint Krishna Kishore Kuchipudi as Director, retire by rotation.

Director profiles

• Snigdha Mothukuri: Hons; master's from Columbia and IIT Madras; prior roles in global firms.
• Nageswar Rao Yarllagadda: 33+ years' leadership; Director at Sri Surya Wheels Pvt Ltd.
• Suryaprakasa Rao Bommisetti: Chartered Accountant; partner at Pundarikashyam & Associates; 30+ years in audit/finance.
• Kolli Srinivas Rao: Chartered Accountant; partner at K Rao & Associates; SEBI/NISM certified.
• Krishna Kishore Kuchipudi: Promoter and MD; BTech; led Jeevan Mita Chit Fund.

Related-party disclosures

• Snigdha Mothukuri is related to Kuchipudi and Kishore.
• No other Directors or KMP are related to each other.
• Kolli Srinivas Rao: no disclosed related-party ties.

Meeting Details

• No meeting date, time, or location disclosed in this chunk.

Key Agenda Items

• No agenda items disclosed in this chunk.

Other Notes

• No other material information available in this chunk.

Dematerialisation status

• Dematerialised securities for quarter ended 30 June 2026 furnished to exchanges.
• RTA confirmed no dematerialisation requests were received during the quarter.